Clark RA, Bessinger R, Kissinger P, Thomas C; International Conference on AIDS.
Int Conf AIDS. 1996 Jul 7-12; 11: 21 (abstract no. We.B.184).
HIV Outpatient Program, Medical Center of Louisiana at New Orleans, New Orleans, LA. Fax: 504-568-5313.
Objective and Methods: Women have comprised less than 3% of subjects enrolled in clinical trials to evaluate the use of megace, a successful therapy for AIDS related wasting. To better understand the effectiveness of megace in women with HIV-related cachexia we undertook a retrospective review of 30 women enrolled into the MCLNO HIV Outpatient Program who were ever prescribed high dose (greater than or equal to 400 mg) megace for wasting. Results: Median CD4 cell count, baseline weight, and weight change over the prior six months at the time of megace initiation were 103/mm3, 114 pounds, and 12 pound weight loss. Fifteen women had been diagnosed with at least one prior opportunistic process (not including wasting syndrome). Only two women had cryptosporidiosis, but 19 women complained of diarrhea. The mean increase in body weight one to three months post-megace treatment was 6.1 pounds (n = 27) and the mean increase at six months was 8.4 pounds (n = 19). Repeated measures analyses were performed on 17 women who had weights available at baseline, three months and six months post-megace. (table: see text) Although women with a CD4 cell count less than 50/mm3 did not sustain their weight gain, the increase over time was significant for the entire cohort (p is less than .01). The only symptom found to be associated with weight gain in women was lack of anorexia following megace treatment (p is less than .005). Conclusion: The results from this study strengthen the recommendation for use of megace as treatment for HIV related cachexia in women with this complication.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Animals
- Anorexia
- Body Weight
- CD4 Lymphocyte Count
- Cachexia
- Drug Therapy, Combination
- Female
- HIV Infections
- HIV Seropositivity
- Humans
- Megestrol Acetate
- Wasting Syndrome
- Weight Gain
- Weight Loss
- drug therapy
- therapy
Other ID:
UI: 102219085
From Meeting Abstracts